Search results: (10000)
News ERS 2022: What Insights Do Studies Focused on COPD Biomarkers Bring?
In this year's scientific program of the international congress of the European Respiratory Society (ERS 2022), there was also a lot of talk about the investigation of biomarkers of chronic obstructive pulmonary disease (COPD) and its acute exacerbations (COPD AE). This topic was also well-represented in the e-poster presentations section. From that section, we select 3 studies whose conclusions are summarized below.
News Conditions for the Use of Mucolytics in Children Are Tightening in Europe − Which Treatment Is Preferred?
There has been a long-standing discussion among experts regarding the benefits of individual mucomodulatory drugs in the treatment of productive cough in children. According to current recommendations, erdosteine remains the preferred treatment for children. At what age can mucolytic treatment be safely recommended?
News Progress on Lorlatinib – What's Next?
Lorlatinib is currently mainly used in the 2nd and later lines of treatment for non-small cell lung cancer (NSCLC) with ALK gene rearrangement. Clinical research is now focusing on the question of how to proceed with patients who experience disease progression during lorlatinib treatment in later lines of therapy. It seems that one of the options might actually be to do nothing – to continue with lorlatinib.
News Inosine pranobex in the treatment of influenza and other respiratory infections of viral etiology
The antiviral inosine pranobex is a clinically proven immunomodulator for the treatment of patients from 1 year of age, indicated for a wide range of diseases with manifestations of immune insufficiency and viral infections. It acts by a direct antiviral effect, modulates the immune system, and also finds application in the treatment of acute viral respiratory diseases, such as influenza and other seasonal viral infections.
News Effect of Itopride on Esophageal Motility and Lower Esophageal Sphincter Function
Itopride is a prokinetic used in the therapy of functional non-ulcerous upper dyspeptic difficulties. The mechanism of action involves inhibition of acetylcholinesterase and antagonism at dopamine D2 receptors. A clinical study by Belgian authors from the Catholic University of Leuven evaluated whether the effect of itopride is due to its influence on esophageal motility and lower esophageal sphincter function.
News Fexofenadine – Non-Sedative and Immunomodulatory Antihistamine in the Treatment of Allergic Symptoms
One of the biggest limitations of traditional antihistamines is the sedative effect on the central nervous system. Newer antihistamines do not cause sedation, are not associated with serious side effects, and some also have immunomodulatory effects.